These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 24249759)
61. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population. Nguyen H; Dufour R; Caldwell-Tarr A Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541 [TBL] [Abstract][Full Text] [Related]
62. A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Montanya E Expert Opin Pharmacother; 2012 Jul; 13(10):1451-67. PubMed ID: 22725703 [TBL] [Abstract][Full Text] [Related]
63. [Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?]. Lüdemann J MMW Fortschr Med; 2011 Jul; 153 Suppl 2():56-63. PubMed ID: 23964469 [TBL] [Abstract][Full Text] [Related]
64. Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. Cuthbertson DJ; Irwin A; Gardner CJ; Daousi C; Purewal T; Furlong N; Goenka N; Thomas EL; Adams VL; Pushpakom SP; Pirmohamed M; Kemp GJ PLoS One; 2012; 7(12):e50117. PubMed ID: 23236362 [TBL] [Abstract][Full Text] [Related]
65. Do current incretin mimetics exploit the full therapeutic potential inherent in GLP-1 receptor stimulation? Nauck MA; Baranov O; Ritzel RA; Meier JJ Diabetologia; 2013 Sep; 56(9):1878-83. PubMed ID: 23748861 [TBL] [Abstract][Full Text] [Related]
66. Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials. Zhang F; Tong Y; Su N; Li Y; Tang L; Huang L; Tong N J Diabetes; 2015 May; 7(3):329-39. PubMed ID: 25043423 [TBL] [Abstract][Full Text] [Related]
67. Liraglutide in oral antidiabetic drug combination therapy. Garber AJ Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265 [TBL] [Abstract][Full Text] [Related]
68. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Ryder RE Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725 [TBL] [Abstract][Full Text] [Related]
70. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. Verge D; López X Curr Diabetes Rev; 2010 Jul; 6(4):191-200. PubMed ID: 20380625 [TBL] [Abstract][Full Text] [Related]
71. The role of glucagon-like peptide 1 receptor agonists for weight control in individuals with acquired hypothalamic obesity-A systematic review. Ng VWW; Gerard G; Koh JJK; Loke KY; Lee YS; Ng NBH Clin Obes; 2024 Jun; 14(3):e12642. PubMed ID: 38273176 [TBL] [Abstract][Full Text] [Related]
72. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Vilsbøll T; Garber AJ Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():41-9. PubMed ID: 22405268 [TBL] [Abstract][Full Text] [Related]
73. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes. Blevins T Postgrad Med; 2010 Jan; 122(1):172-83. PubMed ID: 20107301 [TBL] [Abstract][Full Text] [Related]
75. [Treatment of type 2 diabetes mellitus with GLP-1 agonists]. Haluzík M; Urbanová M; Trachta P Vnitr Lek; 2011 Apr; 57(4):411-5. PubMed ID: 21612070 [TBL] [Abstract][Full Text] [Related]
76. Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? Christensen M; Knop FK Curr Diab Rep; 2010 Apr; 10(2):124-32. PubMed ID: 20425571 [TBL] [Abstract][Full Text] [Related]
77. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Garber AJ Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S279-84. PubMed ID: 21525469 [No Abstract] [Full Text] [Related]
78. Glucagon-like peptide-1 receptor agonists increase pancreatic mass by induction of protein synthesis. Koehler JA; Baggio LL; Cao X; Abdulla T; Campbell JE; Secher T; Jelsing J; Larsen B; Drucker DJ Diabetes; 2015 Mar; 64(3):1046-56. PubMed ID: 25277394 [TBL] [Abstract][Full Text] [Related]
79. Liraglutide: can it make a difference in the treatment of type 2 diabetes? Unger J Int J Clin Pract Suppl; 2010 Oct; (167):1-3. PubMed ID: 20949698 [TBL] [Abstract][Full Text] [Related]
80. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Dushay J; Gao C; Gopalakrishnan GS; Crawley M; Mitten EK; Wilker E; Mullington J; Maratos-Flier E Diabetes Care; 2012 Jan; 35(1):4-11. PubMed ID: 22040840 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]